Ribomic Overview

  • Founded

  • 2003

Founded
  • Status

  • Public

  • Employees

  • 26

Employees
  • Stock Symbol

  • 4591

Stock Symbol
  • Share Price

  • $1.41

  • (As of Thursday Closing)

Ribomic General Information

Description

Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.

Contact Information

Website
www.ribomic.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
TKS
Primary Office
  • Shirokanedai Usui Building 6th Floor
  • 3-16-13 Shirokanedai
  • Tokyo, Minato-ku 108-0071
  • Japan
+81 00-0000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ribomic Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.41 $1.40 $1.06 - $2.10 $40.3M 28.6M 1.76M -$0.53

Ribomic Financials Summary

In Thousands,
USD 		TTM 31-Dec-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 12,655 4,503 29,947 30,223
Revenue 584 720 867 1,116
EBITDA (14,849) (10,935) (7,699)
Net Income (15,577) (14,996) (11,196) (7,864)
Total Assets 37,349 40,594 55,474 21,002
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ribomic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ribomic‘s full profile, request access.

Request a free trial

Ribomic Patents

  • 127

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 9

    Pending

  • 000

    Expiring in next 12 mo

Ribomic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021291555-A1 Aptamer for il-21 and use thereof Pending 17-Jun-2020
CA-3187798-A1 Aptamer for il-21 and use thereof Pending 17-Jun-2020
EP-4122471-A1 Therapeutic agent for subretinal hyperreflective material or retinal disorders accompanying subretinal hyperreflective material Pending 06-Feb-2020 000000000
US-20230065106-A1 Therapeutic agent for subretinal hyperreflective material or retinal disorders accompanying subretinal hyperreflective material Pending 06-Feb-2020 00000000000
US-20220282255-A1 Aptamer for tgf-beta1 and use of same Pending 08-Jul-2019 C12N15/115
To view Ribomic’s complete patent history, request access »

Ribomic Executive Team (1)

Name Title Board Seat Contact Info
Yoshikazu Nakamura Ph.D Founder, President & Chief Executive Officer
To view Ribomic’s complete executive team members history, request access »

Ribomic Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ribomic Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ribomic‘s full profile, request access.

Request a free trial

Ready to get started?

Request a free trial

Ribomic ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Ribomic’s complete esg history, request access »